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S UMM A R Y
S E T T I NG : Of 18 sites that participated in an implemen-
tation study of the Xpertw MTB/RIF assay in India, we
selected five microscopy centres and two reference
laboratories.
OB J E C T I V E : To obtain unit costs of diagnostic tests for
tuberculosis (TB) and drug-resistant TB.
DE S I GN : Laboratories were purposely selected to cap-
ture regional variations and different laboratory types.
Both bottom-up and the top-down methods were used to
estimate unit costs.
R E SU LT S : At the microscopy centres, mean bottom-up
unit costs were respectively US$0.83 (range US$0.60–
US$1.10) and US$12.29 (US$11.61–US$12.89) for
sputum smear microscopy and Xpert. At the reference
laboratories, mean unit costs were US$1.69 for the
decontamination procedure, US$9.83 for a solid culture,
US$11.06 for a liquid culture, US$29.88 for a drug
susceptibility test, and US$18.18 for a line-probe assay.
Top-down mean unit cost estimates were higher for all
tests, and for sputum smear microscopy and Xpert these
increased to respectively US$1.51 and US$13.58. The
difference between bottom-up and top-down estimates
was greatest for tests performed at the reference
laboratories.
CONC LU S I ON : These unit costs for TB diagnostics can
be used to estimate resource requirements and cost-
effectiveness in India, taking into account geographical
location, laboratory type and capacity utilisation.
K E Y WO RD S : tuberculosis; costs; bottom-up; top-
down; diagnostic tests
IMPROVED DIAGNOSTIC TESTING for tubercu-
losis (TB) and drug-resistant TB is one of the pillars of
the global strategy to combat TB.1 New tests have
started to become available and are currently being
implemented.2 The XpertwMTB/RIF assay (Cepheid,
Sunnyvale, CA, USA) was endorsed by the World
Health Organization as a cost-effective test for the
detection of TB and rifampicin (RMP) resistance.1
The scale-up of new diagnostic tests and strategies
for TB and drug-resistant TB have important
economic implications.3 Economic analyses to deter-
mine the cost-effectiveness, affordability or budget-
impact implications of scaling up new diagnostic tests
require reliable cost estimates of diagnostic tests and
procedures.
To assess the feasibility of the Xpert assay roll-out
in India, an implementation study was conducted to
investigate the effect on case detection under
programmatic conditions and assess the cost of the
roll-out.4,5 For an economic analysis of the poten-
tial scale-up of Xpert testing in India, unit cost
estimates of Xpert, sputum smear microscopy
(SSM), as well as of other commonly used tests to
diagnose drug-resistant TB in India, were required.
Earlier TB diagnostic costing studies in India were
from limited settings and conducted during the early
stages of Xpert demonstration studies.6 Costs may
differ at scale and in routine settings.7
We present the unit costs of the Xpert assay, SSM
and other commonly used drug resistance tests in
India across a range of geographic and laboratory
settings. For scale-up purposes, costs estimated by
bottom-up and top-down methods may be equally
important.7 We therefore estimated costs with the
bottom-up or ingredient approach and with the top-
down method, and we present a full capacity costing
of Xpert. These estimates, under different conditions
of service volume, inform scale-up decisions of Xpert
across different sites in India.
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STUDY POPULATION AND METHODS
Setting and selection
We selected laboratories among the 18 sites that were
part of the Xpert implementation study in India,
located in 13 of the 29 states.5 Of the 18 sites, 13 were
part of a hospital and five were located at primary
health care facilities; 6 were located in urban settings,
7 in rural settings and 5 in tribal and hilly areas. To
obtain representative costing estimates for TB diag-
nostic tests, we purposely selected five designated
microscopy centres, 4 of which were located in
hospitals and 1 in a primary health care facility.
Besides variations in the physical location, we
considered variations in workload, urban vs. rural
settings, geographic distribution and proximity to
intermediate reference laboratories (IRLs). The five
microscopy centres selected represented an average
workload of between 89 and 476 patients requiring
TB testing each month. We selected 1 designated
microscopy centre (DMC) in the north of India, 2
DMCs in the south and 2 in the east. Two microscopy
centres were in urban and three in rural settings. To
observe drug resistance tests, we selected two
reference laboratories in close proximity to three of
the five microscopy centres, in the north and the east,
respectively. Table 1 provides an overview of the
laboratory characteristics.
Ethics approval was obtained from the Institution
Ethics Committee of the National Tuberculosis
Institute, Bangalore, India. Approval for the study
was granted by the Central TB Division, Ministry of
Health and Family Welfare, Government of India,
New Delhi, India.
At the DMCs, we observed the Xpert assay and
Ziehl-Neelsen and auramine-stained SSM. At the
IRLs, we observed solid culture on Lo¨wenstein-
Jensen (LJ) medium, liquid culture and drug
susceptibility testing (DST) with the BACTECe
MGITe (Mycobacterium Growth Indicator Tube;
BD, Sparks, MD, USA) system, the GenoTypew
MTBDRplus (Hain Lifescience, Nehren, Germany)
line-probe assay (LPA) v. 2 and M. tuberculosis
rapid speciation (MTB ID). The MGIT DST was
observed for first-line drugs (i.e., RMP, ethambu-
tol, isoniazid and streptomycin). Specimen decon-
tamination was costed as a separate procedure.
The number of observations as well as the
specimen being observed was determined by the
workload on the day of the observation and the
days available at each laboratory. One investigator
(SR) used a stopwatch to time all the activities
required to perform each laboratory procedure.
Observations were made in December 2013 and
January 2014, when the implementation study had
been running for at least 1.5 years at the selected
sites.
Bottom-up vs. top-down
Our primary estimate was the cost of performing a
single test, i.e., the unit cost calculated using the
ingredient approach, where the measured resource
use of the input is multiplied by the cost of the input.
This estimate only includes directly observed
resources, which is different from a top-down
estimate, which takes into account total laboratory
expenditures and allocates them to specific tests.
The top-down method better captures underutilised
resources, as it allocates total cost among all
activities. For example, while in the bottom-up
method the cost of the GeneXpert machine would
be estimated based on inputs used to conduct one
test, in the top-down method the total cost of the
machine is divided by the number of tests. If the
GeneXpert machine is underutilised, top-down
estimates would be higher than bottom-up esti-
mates.
Bottom-up
For each test, we measured resources used for the
preparation, inoculation and incubation of the
specimen, if applicable, and resources used for
Table 1 Characteristics of the laboratories included in the study
DMC #1 DMC #2 DMC #3 DMC #4 DMC #5 IRL #1 IRL #2
State Delhi Assam Assam Andhra
Pradesh
Andhra
Pradesh
Assam Delhi
Urban or rural Urban Urban Rural Rural Rural Urban Urban
Type of laboratory DMC DMC DMC DMC DMC IRL IRL
Year of assessment 2013–2014 2013–2014 2013–2014 2013–2014 2013–2014 2013–2014 2013–2014
Population covered
by each laboratory 4 500000 7804100 3 341550 5 956170 5 375670 NA NA
Persons requiring
diagnostic testing
for TB in 2013, n 4 466 5803 1 160 6 232 4 289 3775 10923
Diagnostic tests
available
SSM, Xpert SSM, Xpert SSM, Xpert SSM, Xpert SSM, Xpert SSM, culture
(solid/liquid),
DST, LPA,
MTB ID
SSM, culture
(solid/liquid),
DST, LPA,
MTB ID
DMC¼ designated microscopy centre; IRL¼ intermediate reference laboratory; NA¼ not available; SSM¼ sputum smear microscopy; DST¼ drug susceptibility
testing; LPA¼ line-probe assay; MTB ID¼M. tuberculosis rapid speciation.
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reporting the results. We collected inputs and their
resources for the following categories: building,
staff, equipment, reagents and chemicals, consum-
ables and overheads. The unit of observation used
for building, staff and equipment was time, for
reagents and chemicals it was the volume used and
for consumables it was the number of units used. We
collected general information about the site, includ-
ing operational minutes and building surface, using
interviews and measurements. Non-observable over-
head costs, such as building costs, administrative
expenses and expenses incurred for utilities, were
first determined through an examination of the
financial records, and then through staff interviews
and laboratory records. As is common in costing
exercises, overhead resources were allocated to tests
based on the amount of staff time or building space
being used to perform the test, as measured during
the observation.8,9 The prices of the equipment,
drugs and medical supplies were provided by the
procurement department of the Foundation for
Innovative New Diagnostics India Office (New
Delhi, India). Where information was not available,
we consulted the United Nations Children’s Fund
Supply Catalogue10 and the Loba Chemie price
list.11 Costs related to buildings and equipment were
annualised over their expected lifetime using a
standard discount rate of 3%.12 For buildings, an
expected lifetime of 30 years was used; for equip-
ment it was set between 2 and 15 years and for
furniture we used 5 years.
All unit costs were calculated in a purpose-built
Excel spreadsheet (MicroSoft, Redmond, WA, USA)
that was developed for TB diagnostic test costing. All
locally collected costs were in Indian rupees (INR)
and are converted to US dollars (USD) using the
exchange rate for March 2014.13
Top-down
In the top-down method, we used expenditure data
and collected figures on the number of Xpert assays
and SSM tests performed annually at each microsco-
py centre. The top-down estimate was calculated by
dividing total annual expenditures on salaries and the
annual cost of buildings and equipment allocated
specifically to each test by the numbers of tests
performed annually. We first divided the total cost of
the building space, the testing equipment (on the basis
of observation) and annual staff salaries by the
annual workload. We then allocated the total
overhead costs per laboratory based on the building
space that was used for either SSM or Xpert testing,
and then also divided by the annual workload. For
reagents and chemicals, and consumables, as annual
expenditure data were unavailable, we used the costs
as estimated in the bottom-up method.
Scenario and sensitivity analyses
To assess the effect of capacity underutilisation on
unit cost for all tests, we compared bottom-up and
top-down estimates. As GeneXpert machines can
simultaneously run 1–4 tests, we also assessed
whether underutilisation of the machine affected
the bottom-up unit costs. We changed all fixed
resources (i.e., building space, equipment, staff and
overheads) as if used at full machine capacity of 8
(two 4-slot machines), instead of the actual ob-
served capacity.
For solid culture, we investigated whether or not
the number of specimens included in an observation
session affected the unit cost. We simulated an
increase in the number of specimens included in the
first observation from 4 (observed) to 26 (number of
specimens included in the second observation).
Resource use increased proportionally.
We validated the annual maintenance cost for
Xpert by comparing the value obtained from stan-
dard formulae that were applied to all tests and
assume an expected lifetime, with annual mainte-
nance costs as observed in the programme.
Cost of the full diagnostic process for drug resistance
Finally, we calculated the cost of the diagnosis of drug
resistance, which requires a diagnostic algorithm, by
summing the bottom-up estimates of all procedures
and tests included in the algorithm.
RESULTS
A total of 32 observations were made to estimate
resource use (Table 2). Using the bottom-up method,
the mean unit cost for SSM was US$0.83, ranging
across observations and sites from US$0.60 to
US$1.10. Using the top-down method, the mean unit
cost for SSM was higher, US$1.51 (range US$0.63–
US$1.84). The mean unit cost for the Xpert assay was
US$12.29 (range US$11.61–US$12.89) using the
bottom-up method and increased to US$13.58 (range
US$11.98–US$16.43) when applying the top-down
method. The mean unit cost per test at reference
laboratories was US$1.69 for the decontamination
procedure, US$9.83 for a solid culture test, US$11.06
for a liquid culture test, US$29.88 for DST, US$18.18
for an LPA and US$3.95 for an MTB ID test with the
bottom-up method; these also increased for all tests
when using the top-down method.
When the GeneXpert machines were used at full
capacity, the bottom-up unit cost fell by 6% to
US$11.58. The bottom-up cost estimate of a solid
culture varied between US$2.29 and US$17.83,
depending on the number of specimens included in
the observation session. Simulating the inclusion of a
larger number of specimens reduced the unit cost
from US$17.83 to US$3.39. The decrease was
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primarily caused by a drop in building costs, of
approximately US$10. In the top-down method, the
same simulation reduced unit costs by 2%.
SSM reagents and chemicals comprised on
average 36% of the mean bottom-up unit cost,
followed by consumables (30%) and overheads
(21%) (Table 3). The composition of the unit cost
changed when the top-down method was used, and
overhead costs comprised on average 40% of the
unit cost, while reagents and chemicals comprised
20%. Regardless of the method used, the cost per
Xpert assay was primarily determined by the cost of
the cartridge (US$9.98), included in the component
reagents and chemicals, and comprised on average
85% of the total unit costs (Table 4). The cost
categories for DST and other TB tests and proce-
Table 3 Mean costs per sputum smear microscopy test in designated microscopy centres (in 2014 USD)
Number of
specimens
observed
Site #1 Site #2 Site #3 Site #4 Site #5
Mean cost across
observations (range)
Proportion
of total
%
Auramine
(n ¼ 7)
Auramine
(n ¼ 10)
ZN
(n ¼ 6)
ZN
(n ¼ 6)
ZN
(n ¼ 6)
ZN
(n ¼ 24)
ZN
(n ¼ 7)
ZN
(n ¼ 8)
ZN
(n ¼ 23)
Bottom-up method
Overhead 0.288 0.211 0.253 0.408 0.13 0.088 0.088 0.083 0.03 0.18 (0.03–0.408) 21.2
Building space 0.098 0.041 0.044 0.025 0.003 0.035 0.039 0.034 0.008 0.04 (0.003–0.098) 4.4
Equipment 0.002 0.002 0.003 0.011 0.003 0.004 0.003 0.003 0.004 0.004 (0.002–0.011) 0.5
Staff 0.053 0.042 0.05 0.036 0.019 0.108 0.104 0.101 0.059 0.06 (0.019–0.108) 7.7
Reagents and
chemicals
0.086 0.086 0.235 0.135 0.285 0.496 0.490 0.571 0.309 0.3 (0.086–0.571) 36.1
Consumables 0.327 0.285 0.215 0.088 0.327 0.192 0.321 0.303 0.185 0.25 (0.088–0.327) 30.1
Total 0.85 0.67 0.8 0.7 0.77 0.92 1.04 1.1 0.6 0.83 (0.6–1.1) 100
Top-down method
Overhead 0.951 0.951 0.951 0.278 0.83 0.435 0.435 0.435 0.153 0.6 (0.153–0.951) 39.8
Building space 0.138 0.138 0.138 0.055 0.015 0.068 0.068 0.068 0.067 0.08 (0.015–0.138) 5.5
Equipment 0.027 0.027 0.027 0.027 0.128 0.019 0.019 0.019 0.035 0.04 (0.019–0.128) 2.4
Staff 0.261 0.261 0.261 0.05 0.251 0.281 0.281 0.281 0.238 0.24 (0.05–0.281) 15.9
Reagents and
chemicals
0.086 0.086 0.235 0.135 0.285 0.496 0.49 0.571 0.309 0.3 (0.086–0.571) 19.8
Consumables 0.327 0.285 0.215 0.088 0.327 0.192 0.321 0.303 0.185 0.25 (0.088–0.327) 16.5
Total 1.79 1.75 1.83 0.63 1.84 1.49 1.61 1.68 0.99 1.51 (0.63–1.84) 100
ZN¼ Ziehl-Neelsen.
Table 2 Number of annual tests, observations per test, specimen per test and unit costs per test*
Test Site(s) Method
Mean annual
number of tests
(min–max)
Number of
observations
Mean number of
specimen per
observations
(min–max)
Mean unit cost
(min–max)
SSM: ZN All 5 DMCs Top-down 8 780 (2 320 –12 464)† NA2 NA 1.44 (0.63–1.84)
Bottom-up NA 7 11.43 (6–24) 0.85 (0.6–1.1)
SSM: auramine All 5 DMCs
þ IRL #2
Top-down 15 389 (4 811–21 846) NA NA 1.89 (1.75–2.13)
Bottom-up NA 3 14 (7–25) 0.84 (0.67–1.01)
Xpert All 5 DMCs Top-down 4 336 (1 384–5 966) NA NA 13.58 (11.97–16.43)
Bottom-up NA 6 4.83 (2–7) 12.29 (11.61–12.89)
Full capacity NA 6 NA 11.58 (10.7–12.72)
Decontamination Both IRLs Top-down 11 805 (6 330–17 280) NA NA 3.38 (2.97–4.45)
Bottom-up NA 4 15 (9–20) 1.69 (0.98–2.3)
Solid culture Both IRLs Top-down 4 453 (2 661–6 245) NA NA 10.94 (7.35–13.16)
Bottom-up NA 3 12.67 (4–26) 9.83 (2.29–17.83)
Liquid culture Both IRLs Top-down 3 747 (1 618–5 875) NA NA 15.95 (10.11–21.79)
Bottom-up NA 2 17 (16–18) 11.06 (9.01–13.12)
DST IRL #2 Top-down 72 NA NA 546.76 (546.22–547.3)
Bottom-up NA 2 3 (2–4) 29.88 (26.34–33.42)
LPA Both IRLs Top-down 3 565 (2 042–5 088) NA NA 33.75 (28.13–39.37)
Bottom-up NA 2 17 (14–20) 18.18 (17.09–19.27)
MTB ID‡ Both IRLs Top-down Unobtainable3 Unobtainable Unobtainable —
Bottom-up NA 2 1 (1–1) 3.95 (3.74–4.16)
*Only data on total microscopy tests were recorded; no distinction was made between ZN and auramine staining.
† Except for ‘reagents and chemicals and consumables’, for which we used the bottom-up method to calculate costs.
‡We were not able to estimate the unit cost with the top-down method as figures on total annual number of tests performed were not known at the time of data
collection.
SSM¼ sputum smear microscopy; ZN¼Ziehl-Neelsen; DMC¼designated microscopy centre; NA¼not applicable; IRL¼ intermediate reference laboratory; DST¼
drug susceptibility testing; LPA¼ line-probe assay; MTB ID¼M. tuberculosis rapid speciation.
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dures performed at the IRLs are presented in the
Appendix.1
Substituting the annual maintenance costs of the
GeneXpert machine calculated using the formulae
with observed annual maintenance costs minimally
increased the average unit costs for the Xpert assay by
respectively 1.7% and 1.6% in the bottom-up and
top-down methods.
The average cost of obtaining a DST profile on a
sample would be equal to US$42.65, if we add the
unit cost of decontamination, liquid culture and DST.
The cost of a full procedure to perform an LPA was
US$20.89, if the costs of decontamination, direct
SSM and LPA are combined.
DISCUSSION
On comparing our findings for the SSM and Xpert
assay with previous results from the demonstration
study in India from 2010,6 we found that the cost of
Xpert was lower, primarily due to the reduced price for
Xpert reagents.14 In addition, cost estimates for
equipment and staff cost components were lower in
our study, possibly due to economies of scale, as we
costed larger sites. Our unit costs for liquid culture,
DST and Xpert were similar to those found in a South
African study.15 Unit costs for SSM were considerably
lower than found in South Africa, explained by the
higher labour costs there, which comprise a large
percentage of SSM unit cost. We also found lower
costs for Xpert than those reported in South Africa,
due to differences in prices of non-tradable goods (such
as salaries) and the fact that we were estimating costs
at full implementation rather than during scale-up.7
Bottom-up unit cost estimates for SSM and Xpert
varied between sites, mostly due to differences in the
use of reagents, chemicals and consumables. Fixed
costs, such as building costs, did not vary substan-
tially between settings. Variations in overhead costs
were primarily related to costs of management staff.
Variations in overheads may also have been due to the
extent of staff time, as this increases the amount of
total overhead costs that are then allocated to SSM.
Differences in the cost of consumables by site were
primarily explained by some staff not wearing
laboratory coats, which is not advised.
For solid and liquid culture, and DST, building
costs comprised a large proportion of unit costs. The
need for a long incubation period in laboratories with
advanced biosafety requirements increased the costs
of utilisation of laboratory space and time in
reference laboratories compared to microscopy cen-
tres. Both bottom-up unit costs and top-down costs
were sensitive to the number of specimens tested per
batch. In the top-down method, a change in the
number of specimens per batch affected the unit cost,
as some of the costs were allocated by dividing the
estimated annual building cost by the annual number
of tests performed. High costs for buildings also
explained the cost difference between direct SSM
Table 4 Mean costs per XpertW MTB/RIF test in designated microscopy centres for all three methods (in 2014 USD)
Number of specimens
observed
Site #1
(n ¼ 7)
Site #2
(n ¼ 10)
Site #3
(n ¼ 6)
Site #4
(n ¼ 6)
Site #5
(n ¼ 24)
Mean cost across
observations (range)
Proportion
of total
%
Ingredient method
Overhead 0.508 0.540 0.172 0.162 0.160 0.036 0.26 (0.036–0.54) 2.1
Building space 0.036 0.021 0.002 0.071 0.073 0.005 0.03 (0.002–0.073) 0.3
Equipment 1.029 1.896 1.254 1.060 1.077 1.241 1.26 (1.029–1.896) 10.2
Staff 0.085 0.045 0.019 0.042 0.040 0.044 0.05 (0.019–0.085) 0.4
Reagents and chemicals 9.980 9.980 9.980 11.368 11.368 9.980 10.44 (9.98–11.368) 85
Consumables 0.273 0.096 0.464 0.169 0.169 0.307 0.25 (0.096–0.464) 2
Total 11.911 12.578 11.891 12.872 12.887 11.613 12.29 (11.61–12.89) 100
Bottom-up method
Overhead 2.017 0.836 2.074 0.379 0.379 0.270 0.99 (0.27–2.074) 7.3
Building space 0.440 0.153 0.063 0.181 0.181 0.118 0.19 (0.063–0.44) 1.4
Equipment 0.950 0.807 3.424 0.766 0.766 1.179 1.32 (0.766–3.424) 9.7
Staff 0.485 0.103 0.421 0.391 0.391 0.602 0.4 (0.103–0.602) 2.9
Reagents and chemicals 9.980 9.980 9.980 11.368 11.368 9.980 10.44 (9.98–11.368) 76.9
Consumables 0.273 0.096 0.464 0.169 0.169 0.307 0.25 (0.096–0.464) 1.8
Total 14.145 11.975 16.426 13.254 13.254 12.456 13.58 (11.97–16.43) 100
Full capacity method
Overhead 0.254 0.135 0.064 0.142 0.140 0.027 0.13 (0.027–0.254) 1.1
Building space 0.018 0.005 0.001 0.062 0.064 0.004 0.03 (0.001–0.064) 0.22
Equipment 0.515 0.474 0.470 0.927 0.942 0.931 0.71 (0.47–0.942) 6.13
Staff 0.042 0.011 0.007 0.037 0.035 0.033 0.03 (0.007–0.042) 0.24
Reagents and chemicals 9.980 9.980 9.980 11.368 11.368 9.980 10.44 (9.98–11.368) 90.19
Consumables 0.273 0.096 0.464 0.169 0.169 0.307 0.25 (0.096–0.464) 2.13
Total 11.082 10.701 10.987 12.704 12.717 11.281 11.58 (10.7–12.72) 100
1 The appendix is available in the online version of this article, at
http://www.ingentaconnect.com/content/iuatld/ijtld/2017/
00000021/00000004/art00005
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(US$1.01) at the microscopy centres and SSM
performed on liquid culture isolates at the reference
laboratories (US$7.70). For DST, top-down cost
estimates were much higher than the bottom-up
approach because the use of DST (n ¼ 72) was low
compared to the other tests, suggesting a high level of
excess capacity in DST resourcing.
Not surprisingly, we generally found top-down
costs to be higher than bottom-up costs. There was
one exception, likely due to measurement bias by the
staff when using a bottom-up method. In this case,
some staff may take longer to perform a test than
usual. The top-down method increased the mean
unit cost across sites for SSM by 80% and for the
Xpert assay by 11% compared to the bottom-up
method. This suggests underutilisation of current
diagnostic capacity. The smaller proportional dif-
ference for the Xpert assay is because a higher
proportion of the cost of Xpert is due to items such
as consumables, where ‘excess capacity’ is unlikely
to occur. This difference in top-down and bottom-up
costs therefore suggests that further scale-up of
interventions could lead to improvements in effi-
ciency and cost reductions,7 as capacity in resources
such as building and staff become better utilised. A
scale-up may also enhance the knowledge of staff,
which could lead to improved efficiency in process-
es, and possibly task shifting to more junior staff
over time, which may also further reduce costs.
In conclusion, we obtained unit costs for TB
diagnostics across different settings in India, taking
into account geographical location, laboratory type
and capacity utilisation. These costs suggest room
for further efficiencies and provide an essential base
for estimating resource requirements and the cost-
effectiveness of Xpert roll-out in India.
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APPENDIX
Table A.1 Cost per test in IRL#1 (in 2014 USD)
Number of specimens observed
Decontamination
(n ¼ 9)
Culture: solid
(n ¼ 4)
Culture: solid
(n ¼ 8)
Culture: liquid
(n ¼ 16)
LPA
(n ¼ 14)
MTB ID
(n ¼ 1)
Bottom-up method
Overhead 0.201 1.658 0.890 0.478 0.853 0.101
Building space 0.506 11.925 6.004 9.064 0.042 1.090
Equipment 0.219 3.371 1.701 0.457 1.274 0.528
Staff 0.105 0.095 0.109 0.067 1.150 0.055
Reagents and chemicals 0.662 0.446 0.456 0.433 13.382 1.400
Consumables 0.603 0.337 0.225 2.616 2.567 0.564
Total 2.296 17.832 9.385 13.115 19.268 3.738
Top-down method
Overhead 0.952 4.858 4.858 4.858 4.123 NA
Building space 0.970 3.654 3.654 3.796 5.889 NA
Equipment 0.802 1.907 1.156 6.859 4.481 NA
Staff 0.460 1.962 1.962 3.227 8.931 NA
Reagents and chemicals 0.662 0.446 0.456 0.433 13.382 —
Consumables 0.603 0.337 0.225 2.616 2.567 —
Total 4.449 13.165 12.311 21.789 39.374 NA
IRL¼ intermediate reference laboratory; LPA¼ line-probe assay; MTB ID¼M. tuberculosis rapid speciation; NA¼ not applicable.
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R E S U M E
CONT EX T E : Parmi les 18 sites qui ont participe´ a` une
e´tude de mise en œuvre du test Xpertw MTB/RIF en
Inde, nous avons se´lectionne´ cinq centres de microscopie
et deux laboratoires de re´fe´rence.
OB J E C T I F : Obtenir les couˆts unitaires des tests de
diagnostic de la tuberculose (TB) et de la TB
pharmacore´sistante.
S CH E´MA : Les laboratoires ont e´te´ se´lectionne´s de fac¸on
a` eˆtre repre´sentatifs des variations re´gionales et des
diffe´rents types de laboratoire. Des me´thodes
ascendantes et descendantes ont e´te´ utilise´es afin de
calculer les couˆts par unite´.
R E´ S U LTAT S : Dans les centres de microscopie, les couˆts
unitaires moyens ascendants ont e´te´ de US$0,83
(fourchette US$0,60–US$1,10) et de US$12,29
(US$11,61–US$12,89) pour le frottis de crachats et
l’Xpert, respectivement. Dans les laboratoires de
re´fe´rence, les couˆts unitaires moyens ont e´te´ de
US$1,69 pour la proce´dure de contamination, de
US$9,83 pour la culture en milieu solide, de US$11,06
pour la culture en milieu liquide, de US$29,88 pour un
test de pharmacosensibilite´ et de US$18,18 pour un test
de sonde en ligne. Les estimations des couˆts unitaires
moyens descendants ont e´te´ plus e´leve´es pour tous les
tests et pour le frottis de crachats et l’Xpert ont
augmente´ a` US$1,51 et a` US$13,58, respectivement.
Les diffe´rences entre les estimations ascendantes et
descendantes ont e´te´ les plus importantes pour les tests
re´alise´s dans les laboratoires de re´fe´rence.
CONC LU S I ON : Ces couˆts unitaires du diagnostic de la
TB peuvent eˆtre utilise´s pour estimer les besoins en
ressources et la rentabilite´ en Inde, en tenant compte de
la localisation ge´ographique, de type de laboratoire et de
sa capacite´ d’utilisation.
R E S UM E N
MAR CO D E R E F E R E N C I A: De los 18 centros que
participaron en un estudio de aplicacio´n de la prueba
Xpertw MTB/RIF en la India, se escogieron cinco
centros de microscopia y dos laboratorios de referencia.
OB J E T I VO: Conocer los costos unitarios de las pruebas
diagno´sticas de la tuberculosis (TB) y la TB
farmacorresistente.
M E´ TODO: Se practico´ un muestreo intencional con el fin
de captar las diferencias en las regiones y en los diversos
tipos de laboratorios. La estimacio´n de los costos
unitarios se obtuvo mediante me´todos de ca´lculo
descendente y ascendente.
R E S U LTA DO S: En los centros de microscopia, las
estimaciones ascendentes revelaron un costo unitario
promedio de la baciloscopia del esputo de US$0,83
(entre US$0,60 y US$1,10) y de la prueba Xpert de
US$12,29 (entre US$11,61 y US$12,89). En los
laboratorios de referencia el promedio de los costos
unitarios fueron US$1,69 por procedimiento de
descontaminacio´n US$1,69; US$9,83 por cultivo en
medio so´lido; US$11,06 por cultivo en medio lı´quido;
US$29,88 por prueba de sensibilidad a los
medicamentos; y US$18,18 por cada prueba molecular
con sondas en lı´nea. Las estimaciones descendentes
revelaron un costo unitario promedio ma´s alto para
todas las pruebas, pues el costo de la baciloscopia del
esputo aumento´ a US$1,51 y el costo de la prueba Xpert
a US$13,58. Las diferencias entre las estimaciones
ascendentes y descendentes fueron ma´s grandes con las
pruebas realizadas en los laboratorios de referencia.
CONC LU S I O´ N: Estos costos unitarios de las pruebas
diagno´sticas de la TB se pueden utilizar con el fin de
calcular la necesidad de recursos y la relacio´n de costo-
efectividad de las intervenciones en la India, teniendo en
cuenta la ubicacio´n geogra´fica, el tipo de laboratorio y la
utilizacio´n de las capacidades existentes.
TB diagnostic tests costs India iii
